关键词：细菌性结膜炎；传染性眼；结膜感染；微生物；广谱抗生素
摘 要：Bacterial conjunctivitis, which affects either one or both the eyes, is an extremely contagious eye condition wherein the conjunctiva is infected. Staphylococci, streptococci, gonococci, and Chlamydia are some of the causative agents of bacterial conjunctivitis. Extremely pathogenic bacteria such as Chlamydia trachomatis and Neisseria gonorrhea cause severe bacterial conjunctivitis. Antibiotics help in eradicating the microbes, resulting in faster clearance of the symptoms. Broadspectrum antibiotics such as Besivance, Zymaxid, Maxitrol, and AzaSite, in the form of antibiotic pills, ointment, or eye drops help treat the infection. Fluoroquinolones, macrolides, aminoglycosides, and phenicols are among the different classes of antibiotics that are commonly prescribed to treat the condition.
目 录：

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Overview: Bacterial conjunctivitis

Conjunctivitis

Bacterial conjunctivitis

Signs and symptoms

Diagnosis

Management

Economic burden

PART 06: Pipeline analysis

FST-100

AzaSite Xtra (ISV-405)

PART 07: Antimicrobial resistance

Initiatives to improve innovation of antibiotics

PART 08: Legislation relating to antibiotic use in US

PART 09: Market landscape

Market overview

Market size and forecast

Bacterial conjunctivitis drugs market in US

Five forces analysis

PART 10: Market segmentation by drug class

Fluoroquinolones

Aminoglycosides

Macrolides

Other

PART 11: Geographical segmentation

Global bacterial conjunctivitis drugs market by geography

2015-2020

Bacterial conjunctivitis drugs market in Americas

Bacterial conjunctivitis drugs market in EMEA

Bacterial conjunctivitis drugs market in APAC

PART 12: Market drivers

Rising awareness about infection

Development of multidrug-resistant variants

Prevalence of bacterial conjunctivitis

PART 13: Impact of drivers

PART 14: Market challenges

Patent expiry of drugs

Contentment with existing therapies

Adverse effects and limited efficacy of drugs

Weak R&D of drugs

PART 15: Impact of drivers and challenges

PART 16: Market trends

Strategic alliances and M&A

Use of combination therapies

Patient assistance programs

PART 17: Vendor landscape

Competitive scenario

Akorn

Alcon

Allergan

Bausch & Lomb

Other prominent vendors

PART 18: Appendix

List of abbreviations

PART 19: Explore Technavio